Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business
RGEN•Deal terms, rationale and expected savings
BioLife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen for each share, valuing the cell therapy tools supplier at $31 per share — a premium of about 6.2% to BioLife's last close.
The boards of both companies have unanimously approved the deal, which is expected to close in the fourth quarter of 2026, pending regulatory and shareholder approvals.
The acquisition is expected to increase Repligen's earnings and generate at least $20 million in savings in the first year after closing by cutting overlapping costs and improving efficiency, the company said.
Repligen to acquire BioLife for about $1.5 billion
July 22 (Reuters) - Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal valued at about $1.5 billion, to expand the drugmaking equipment provider's presence in the fast-growing cell therapy market.
Shares of BioLife rose about 3% in premarket trading.
The acquisition gives Repligen access to BioLife's technology to preserve cells throughout the manufacturing process and the supply chain, as well as its portfolio of cell-processing tools and high-margin consumables business.
Strategic context for the cell therapy tools market
BioLife's products are used in about 90% of commercially approved cell therapies, William Blair analyst Matt Larew said.
